移植后环磷酰胺预防接受错配无关供者造血干细胞移植患者的移植物抗宿主病:PHYLOS试验
PHYLOS是一项前瞻性单臂2期研究,由意大利骨髓移植组在26个意大利移植中心开展,2020年1月至2022年11月连续纳入77例急性髓系恶性肿瘤患者(急性髓系白血病64例、骨髓增生异常综合征13例),中位年龄53岁(范围19-65岁),评估移植后高剂量环磷酰胺预防错配无关供者造血干细胞移植后急性移植物抗宿主病的疗效。结果显示100天2-4级急性移植物抗宿主病累积发生率为18.2%(95%CI 10.6-27.6),3-4级为6.5%(95%CI 3.1-15.1),1年总生存率为78.6%(95%CI 67.4-86.3)。作者认为移植后环磷酰胺可降低急性移植物抗宿主病发生率并改善错配无关供者移植的临床结局。
要点
- 100天2-4级急性移植物抗宿主病累积发生率为18.2%(95%CI 10.6-27.6),3-4级为6.5%(95%CI 3.1-15.1)。
- 71例(92%)患者在移植后第+30天实现供者完全嵌合及中性粒细胞完全植入。
- 1年总生存率78.6%(95%CI 67.4-86.3),无移植物复发生存率55.3%(95%CI 43.4-65.7)。
核心结论
- 作者认为,在 homogeneous 患者队列中,移植后环磷酰胺可带来较低的急性移植物抗宿主病发生率并改善错配无关供者造血干细胞移植的临床结局。
研究设计与样本
- 前瞻性、单臂、2期研究(PHYLOS),由意大利骨髓移植组开展,参与中心伦理委员会批准(EURODRACT 2017-003530-85)。
- 共连续纳入77例急性髓系恶性肿瘤患者(急性髓系白血病64例、骨髓增生异常综合征13例),来自26个意大利移植中心,入组时间2020年1月至2022年11月。
- 患者中位年龄53岁(范围19-65岁)。
- 试验注册于www.clinicaltrials.gov,注册号NCT03270748。
主要发现
- 100天2-4级急性移植物抗宿主病累积发生率为18.2%(95%CI 10.6-27.6),3-4级为6.5%(95%CI 3.1-15.1)。
- 71例患者(92%)在移植后第+30天实现供者完全嵌合及中性粒细胞完全植入。
- 1年慢性移植物抗宿主病累积发生率为13.4%(95%CI 6.9-22.1)。
- 1年非复发死亡累积发生率为9.1%(95%CI 4.0-16.9),复发率为23.8%(95%CI 14.9-33.9)。
- 1年总生存率为78.6%(95%CI 67.4-86.3),无移植物复发生存率为55.3%(95%CI 43.4-65.7)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Posttransplant high-dose cyclophosphamide (PTCy) is effective in overcoming the negative impact of HLA disparity in the haploidentical setting. In light of these results, we investigated the efficacy of PTCy, in improving clinical outcomes of hematopoietic stem cell transplantation (HSCT) from a mismatched unrelated donor (MMUD) in patients with acute myeloid malignancies by reducing the incidence and severity of acute graft-versus-host disease (aGVHD). A prospective, single-arm, phase 2 study (PHYLOS) was conducted by the Gruppo Italiano Trapianto di Midollo Osseo. The ethical committees of the participating centers approved the study (EURODRACT 2017-003530-85). A total of 77 consecutive patients (acute myeloid leukemia: 64; myelodysplastic syndrome: 13) were enrolled at 26 Italian transplant centers (January 2020-November 2022). Median age of the patients was 53 (range, 19-65) years. The 100-day cumulative incidence of grades 2 to 4 aGVHD was 18.2% (95% CI, 10.6-27.6) and of grades 3 to 4 was 6.5% (95% CI, 3.1-15.1). Seventy-one patients (92%) had full-donor chimerism with complete neutrophil engraftment by day +30. One-year cumulative incidence of chronic GVHD was 13.4% (95% CI, 6.9-22.1). One-year cumulative incidence of nonrelapse mortality was 9.1% (95% CI, 4.0-16.9), and the relapse rate was 23.8% (95% CI, 14.9-33.9). One-year overall survival and graft relapse-free survival were 78.6% (95% CI, 67.4-86.3) and 55.3% (95% CI, 43.4-65.7), respectively. Our study in a homogeneous patient cohort suggests that PTCy leads to a low rate of aGVHD and improves clinical outcomes of HSCT from MMUD. This trial was registered at www.clinicaltrials.gov as #NCT03270748.
引用
- Raiola AM, Bruno B, Risitano AM, et al. Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trial. Blood Adv. 2025. PMID: 39928954. doi:10.1182/bloodadvances.2024015173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。